Search Results for "protease inhibitors"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for protease inhibitors. Results 61 to 64 of 64 total matches.
A 4-Drug Combination (Viekira Pak) for Hepatitis C
The Medical Letter on Drugs and Therapeutics • Feb 02, 2015 (Issue 1461)
have a history of treatment failure
with an HCV protease inhibitor (telaprevir, boceprevir,
simeprevir).
Table ...
The FDA has approved Viekira Pak (Abbvie), a fixed-dose
combination of two new direct-acting antiviral
agents (ombitasvir, paritaprevir) with the pharmacologic
enhancer ritonavir in one tablet, co-packaged with
a third new direct-acting antiviral agent (dasabuvir) in
a second tablet, for oral treatment of chronic hepatitis
C virus (HCV) genotype 1 infection. Genotype 1 is
responsible for 70-80% of HCV infections in the US.
Two Vonoprazan Combinations (Voquezna) for H. pylori
The Medical Letter on Drugs and Therapeutics • Oct 31, 2022 (Issue 1662)
allopurinol and
amoxicillin
Antiretrovirals
Possible increased/decreased serum concentrations of protease ...
The FDA has approved vonoprazan, a potassium-competitive
acid blocker, copackaged with amoxicillin
(Voquezna Dual Pak – Phathom) and with amoxicillin
and clarithromycin (Voquezna Triple Pak) for
treatment of Helicobacter pylori infection in adults.
Vonoprazan is the first potassium-competitive acid
blocker to be approved in the US. It has been available
in Japan for treatment of various acid-related
disorders since 2014. Vonoprazan is not available
alone in the US.
Antiviral Drugs
Treatment Guidelines from The Medical Letter • Mar 01, 2013 (Issue 127)
for genotype 2 or 3);
when a protease inhibitor is added, PR treatment duration should be based
on patient ...
The drugs of choice for treatment of viral infections
(other than HIV) and their dosages are listed in Tables
1-6 on the pages that follow. Some of the indications
and dosages recommended here have not been
approved by the FDA. Vaccines used for the prevention
of viral infections are discussed elsewhere.
Table: Treatments Considered for COVID-19 (Archived) (online only)
The Medical Letter on Drugs and Therapeutics • Apr 06, 2020 (Issue 1595)
InteractionsCommentsHIV Protease Inhibitors
Atazanavir1 (ATV) –
Reyataz (BMS) and generics
Dosage
Optimal dosage ...
View the Table: Treatments Considered for COVID-19